The numbers are good. If you go & look at some post hoc analysis of Cana, there was a broad range in reduction of UACR dependent on starting baseline.
The subgroup in DKD DMX-200 trial 500mg/L or greater achieved a 37-38% reduction in UACR. Compare that to the above of 31% at week 26 with a cohort of >300mg/L. We know from the CREDENCE trial that UACR & eGFR decline & then plateau at 26 weeks.
I’m sure there is loads to discuss here, catch up later
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-19
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.5¢ |
Change
0.025(5.32%) |
Mkt cap ! $275.7M | |||
| Open | High | Low | Value | Volume |
| 47.5¢ | 51.0¢ | 46.5¢ | $2.092M | 4.240M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 20294 | 49.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 211551 | 6 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |